A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine

Journal of Psychopharmacology

Volumn 26, Issue 9, 2012, Pages 1175-1184

  Sherwood, Megan ^a,b,c   Thornton, Allen E ^b,d   Honer, William G ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BC Mental Health and Addictions Research Institute   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d SIMON FRASER UNIVERSITY   (Canada)

Author keywords

antipsychotic; BPRS; Clozapine; PANSS; schizophrenia

Indexed keywords

BENZATROPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; QUANTITATIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 84864997115     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112440513     Document Type: Review

References (52)

1. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003 ; 60: 1228-1235
2. Agid O, Kapur S, Warrington L, et al. Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophrenia Res. 2008 ; 102: 241-248
3. Bitter I, Dossenbach MR, Brook S, et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004 ; 28: 173-180
4. Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study. Am J Psychiatry. 1998 ; 155: 499-504
5. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry. 2001 ; 158: 518-526
6. Chen L, Ascher-Svanum H, Stauffer V, et al. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophrenia Res. 2009 ; 113: 34-40
7. Claghorn J, Honigfeld G, Abuzzahab FS, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol. 1987 ; 7: 377-384
8. Cohen J Statistical Power Analysis for the Behavioral Sciences. Hillsdale, New Jersey: Lawrence Erlbaum Associates ; 1988 :
9. Conley RR, Carpenter WT, Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry. 1997 ; 154: 1243-1247
10. Correll CU, Malhotra AK, Kaushik S, et al. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003 ; 160: 2063-2065
11. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry. 2006 ; 163: 743-745
12. Farde L, Nordström A-L, Wiesel F-A, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry. 1992 ; 49: 538-544
13. Fischer-Cornelssen KA, Ferner UJ. An example of European multicenter trials: multispectral analysis of clozapine. Psychopharmacol Bull. 1976 ; 12: 34-39
14. Gelenberg AJ, Doller JC. Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study. J Clin Psychiatry. 1979 ; 40: 238-240
15. Glick ID, Shkedy Z, Schreiner A. Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. Int Clin Psychopharmacol. 2006 ; 21: 261-266
16. Gunduz-Bruce H, McMeniman M, Robinson DG, et al. Duration of untreated psychosis and time to treatment response for delusions and hallucinations. Am J Psychiatry. 2005 ; 162: 1966-1969
17. Heinrich K, Klieser E, Lehmann E, et al. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog Neuro-Psychopharmacol Biol Psychiatry. 1994 ; 18: 129-137
18. Honer WG, Procyshyn RM, Chen EYH, et al. A translational research approach to poor treatment response in schizophrenia: clozapine- antipsychotic polypharmacy. J Psychiatry Neurosci. 2009 ; 34: 433-442
19. Honigfeld G, Patin J, Singer J. Clozapine antipsychotic activity in treatment-resistant schizophrenics. Adv Therapy. 1984 ; 1: 77-97
20. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996 ; 17: 1-12
21. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine/benztropine. Arch Gen Psychiatry. 1988 ; 45: 789-796
22. Kane JM, Marder SR, Schooler NR, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry. 2001 ; 58: 965-972
23. Kapur S, Arenovich T, Agid O, et al. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry. 2005 ; 162: 939-946
24. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999 ; 156 (2). 286-293
25. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Res. 2008 ; 102: 230-240
26. Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacol. 2010 ; 35: 581-590
27. Klieser E, Strauss WH, Lemmer W. The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia. Acta Psychiat Scand. 1994 ; 380S: 68-73
28. Kluge M, Schuld A, Himmerich H, et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol. 2007 ; 27: 662-666
29. Leucht S, Busch R, Hamann J, et al. Early-onset hypothesis of drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry. 2005 ; 57: 1543-1549
30. Leucht S, Busch R, Kissling W, et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry. 2007 ; 68: 352-360
31. Leucht S, Heres S, Hamann J, et al. Methodological issues in current antipsychotic drug trials. Schizophrenia Bull. 2008 ; 34: 275-285
32. Li M, Fletcher PJ, Kapur S. Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacol. 2007 ; 32: 263-272
33. Li Y, Wang C-H, Zhang DH, Wang LH, et al. A study of quetiapine and clozapine in the treatment of first episode schizophrenia. Chinese J Nerv Mental Dis. 2002 ; 28: 219-220
34. Lieberman JA, Tollefson GD, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode paychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003 ; 160: 1396-1404
35. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006 ; 163: 600-610
36. Meltzer HY, Bastani B, Kwon KY, et al. A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology. 1989a ; 99: S68 - S72
37. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989b ; 25: 390-392
38. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiat Scand. 2006 ; 114: 3-13
39. Potter WZ, Ko GN, Zhang LD, et al. Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology. 1989 ; 99S: 587-591
40. Raedler TJ, Schreiner A, Naber D, et al. Early onset of treatment effects with oral risperidone. BMC Psychiatry. 2007 ; 7: 4
41. Rosenthal R, Rosnow RL Essentials of Behavioral Research: Methods and Data Analysis. New York: McGraw Hill ; 1991 :
42. Sacchetti E, Galluzzo A, Valsecchi P, et al. Ziprasidone versus clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophrenia Res. 2009 ; 110: 80-89
43. Sherwood M, Thornton AE, Honer WG. A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics. Int J Neuropsychopharmacol. 2005 ; 9: 1-10
44. Shopsin B, Klein H, Aaronsom M, et al. Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison. Arch Gen Psychiatry. 1979 ; 36: 657-664
45. Singer K, Law SK. A double-blind comparison of clozapine (leponex) and chlorpromazine in schizophrenia of acute symptomatology. J International Med Res. 1974 ; 2: 433-435
46. Small JG, Kolar MC, Kellams JJ. Quetiapine in schizophrenia: onset of action within the first week of treatment. Curr Med Res Opin. 2004 ; 20: 1017-1023
47. Stein D, Schonell H, Klieser E Biologische Psychiatrie 2: Drei-Länder-Symposium für Biologische Psychiatrie. Saletu B, ed. Stuttgart: Georg Thieme Verlag ; 1989: 268-270.
48. Tauscher J, Hussain T, Agid O, et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry. 2004 ; 161: 1620-1625
49. Tollefson GD, Birkett MA, Kiesler GM, et al. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001 ; 49: 52-63
50. van den Oord EJ, Adkins DE, McClay J, et al. A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophrenia Res. 2009 ; 107: 13-21
51. Wang C, Feng Y, Want L. A double-blind randomized controlled study of olanzapine and clozapine on treatment of schizophrenia. Shanghai Arch Psychiatry. 2002 ; 14: 143-145
52. Woerner MG, Robinsn DG, Alvir JM, et al. Clozapine as a first treatment for schizophrenia. Am J Psychiatry. 2003 ; 160: 1514-1516